|
|
Bleph-10 (Sulfacetamide sodium)
|
 |
Ophthalmic/Otic agent
|
 |
Sulfonamide
|
 |
For the treatment of Conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma.
|
 |
For Conjunctivitis and other superficial ocular infections: Instill 1 or 2 drops into the conjunctival sac(s) of the affected eye(s) every 2 to 3 hours initially. Dosages may be tapered by increasing the time interval between doses as the condition responds. The usual duration of treatment is 7 to 10 days. For trachoma: Instill 2 drops into the conjunctival sac(s) of the affected eye(s) every 2 hours. Topical administration must be accompanied by systemic administration
|
 |
Category C
|
 |
Local irritation, stinging, burning, and hypersensitivity.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
